Drug target interaction of tubulin-binding drugs in cancer therapy

Expert Review of Anticancer Therapy

Volumn 6, Issue 10, 2006, Pages 1433-1447

  Sengupta, Suparna ^a   Thomas, Sannu Ann ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Colchicine; Interaction parameters; Microtubules; Taxol; Tubulin; Vinca alkaloids

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; COLCEMEID; COLCHICINE; COLCHICINOID DERIVATIVE; COMBRETASTATIN; COMBRETASTATIN A4; CYCLOSTREPTIN; CYTOTOXIC AGENT; DICTYOSTATIN; DISCODERMOLIDE; DOCETAXEL; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; ESTRADIOL DERIVATIVE; ETOPOSIDE; NAVELBINE; NOCODAZOLE; PACLITAXEL; PODOPHYLLOTOXIN; SARCODICTYIN A; SARCODICTYIN B; SULFONAMIDE; TACCALONOLIDE DERIVATIVE; TAXOID; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DRUG BINDING SITE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE; NONHUMAN; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PROTEIN BINDING; TUBULIN;

EID: 33750701126     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.10.1433     Document Type: Review

References (124)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004).
2. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2, 1-17 (2002).
3. Wilson L, Panda D, Jordan MA. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cell regulators. Cell Struct. Funct. 24, 329-335 (1999).
4. Burkhart CA, Kavallaris M, Horwitz SB. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochem. Biophys. Acta 2, 1-9 (2001).
5. Kavallaris M, Tait AS, Walsh BJ et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res. 61, 5803-5809 (2001)
6. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules Oncogene 22, 7280-7295 (2003).
7. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J. 19, 1299-12301 (2005).
8. Rao S, Krauss NE, Heerding JM et al. 3′-(p-azidobenzamido)taxol photolabels - the N-terminal 31 amino acids of β-tubulin. J. Biol. Cbem. 269, 3132-3134 (1994).
9. Dasgupta D, Park H, Harriman GCB, Georg GI, Himes RH. Synthesis of a photoaffinity taxol analogue and its use in labeling tubulin. J. Med. Chem. 37, 2976-2980 (1994).
10. Combeau C, Commercon A, Miskowski C, Rousseau B, Aubert F. Goeldner M. Predominant labeling of β- over α-tubulin from porcine brain by a photoactivatable taxoid derivative. Biochemistry 33, 6676-6683 (1994)
11. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KA. Structure of tubulin at 6.5A and location of the taxol-binding site. Nature 375, 424-427 (1995).
12. Choy H. Taxanes in combined modality therapy for solid tumors. Crit. Rev. Oncol. hematol. 37, 237-247 (2001).
13. Caplow M, Shanks J. Ruhlen R. How taxol modulates microtubule disassembly. J. Biol. Chem. 269, 23399-23402 (1994).
14. Buey RM, Barasoain I, Jackson E et al. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem. Biol. 12, 1269-1279 (2005).
15. Sengupta S, Boge TC, Georg GI, Himes RH. Interaction of a fluorescent paclitaxel analogue with tubulin. Biochemistry 34, 11889-11894 (1995).
16. Carlier MF, Pantaloni D. Taxol effect on tubulin polymerization and associated guanosine 5′-triphosphate hydrolysis. Biochemistry 22, 4814-4822 (1983).
17. Han Y. Chaudhary AG, Chordia MD et al. Interaction of a fluorescent derivative of paclitaxel (Taxol) with microtubules and tubulin-colchicine. Biochemistry 35, 14173-14183 (1996).
18. Sengupta S, Boge TC, Liu Y, Hepperle M, Georg GI, Himes RH. Probing the environment of tubulin-bound paclitaxel using fluorescent paclitaxel analogs. Biochemistry 36, 5179-5184 (1997).
19. Georg GI, Boge TC, Cheruvallath ZS et al. Schotten-Baumann acylation of N-debenzoyltaxol: an efficient route to -acyl taxol analogs and their biological evaluation. Bioorg. Med, Chem. Lett. 4, 335-338 (1994).
20. Hepperle M, George GI. Taxol analogs. Drugs Future 19, 573-584 (1994)
21. Vici P, Belli F, Lauro LD et al. Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology 60, 60-65 (2001).
22. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325-2333 (1995).
23. Buey RM, Diaz JF, Andreu JM et al. Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem. Biol. 11, 225-236 (2004).
24. ter Haar E, Kowaiski RJ, Hamel E et al. Discodermolicle, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35, 243-250 (1996).
25. Minguez JM, Giuliano KA, Balachandran R, Madiraju C, Curran DR, Day BW. Synthesis and high content cell-based profiling of simplified analogs of the microtubule stabilizer (+)-discodermolide. Mol. Cancer Therapeutics 1. 1305-1313 (2002).
26. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. ANZ J. Med. 17, 301-304 (1987).
27. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N. Engl. J. Med. 291, 932-934 (1974).
28. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl. J. Med. 291, 934-937 (1974).
29. Das L, Datta AB, Cupta S et al, -NH-dansyl isocolchicine exhibits a significantly improved tubulin-binding affinity and microtubule inhibition in comparison to isocolchicine by binding tubulin through its A and B rings. Biochemisty 44, 3249-3258 (2005).
30. Capraro HG, Brossi A. The Alkaloids. Brossi A, (Ed.). Academic Press, New York, USA, 1-70 (1984).
31. Ravelli RBG, Cigant B, Curmi PA et al. Insight into tubulin regulation from a complex with colchicine and a stathmin like domain. Nature 428, 198-202 (2004).
32. Wolff J, Knipling L, Cahnmann HJ, Palumbo G. Direct photoaffinity labeling of tubulin with colchicine. Proc. Natl Acad. Sci. USA 88, 2820-2824 (1991).
33. Rosner M, Capraro HG, Jacobson AE et al. Biological effects or modified colchicines. Improved preparation of 2-demethylcolchicine, 3-demethylcolchicine, and (+)-colchicine and reassignment of the position of the double bond in dehydro-7-deacetamidocolchicines. J. Med. Chem. 24, 257-261 (1981).
34. Medrano FJ, Andreu JM, Gorbunoff MJ, Timasheff SN. Roles of ring C oxygens in the binding of colchicine. Biochemistry 28, 5589-5599 (1998).
35. Ray K, Bhattacharyya B, Biswas BB. Role of B-ring of colchicine in its binding to tubulin. J. Biol. Chem. 256, 6241-6244 (1981).
36. Chakrabarti G, Sengupta S, Bhattacharyya B. Thermodynamics of colchicinoids-tubulin interactions, role of B-ring and C-7 substituent. J. Biol. Chem. 271, 2897-2901 (1996).
37. Diaz JF, Andreu JM. Kinetics of dissociation of the tubulin-colchicine complex. J. Biol. Chem. 266, 2883-2889 (1991).
38. Bane S, Puett D, MacDonald TL, Williams RC Jr. Binding to tubulin of the colchicine analog 2-methoxy-5-(2′,3′,4′-trimethoxyphenyl)tropone: thermodynamic and kinetic aspects. J. Biol. Chem. 259, 7391-7398 (1984).
39. Bhattacharyya B, Howard R, Maity SN, Brossi A, Sharma PN, Wolff J. B-ring regulation of colchicine binding kinetics and fluorescence. Proc. Natl Acad. Sci. USA 83, 2052-2055 (1986).
40. Garland DL. Kinetics and mechanism of colchicine binding to tubulin: evidence for ligand-induced conformational change. Biochemistry 17, 4266-4272 (1978).
41. Detrich HW III, Williams RC Jr, Macdonald TL, Wilson L, Puett D. Changes in the circular dichroic spectrum of colchicine associated with its binding to tubulin. Biochemistry 20, 5999-6005 (1981).
42. Andreu JM, Timasheff SN. Conformational states of tubulin liganded to colchicine, tropolone methyl ether, and podophyllotoxin. Biochemistry 21, 6465-6476 (1982).
43. Bhatacharyya B, Wolff J. Promotion of Fluorescence upon binding of colchicine to tubulin. Proc. Natl Acad. Sci. USA 71, 2627-2631 (1974).
44. Banerjee A, Luduena RF. Kinetics of colchicine binding to purified β-tubulin isotypes from bovine brain. J. Biol. Chem. 267, 13335-13339 (1992).
45. Banerjee A, D'Hoore A, Enjelborghs Y. Interaction of desacetamido-colchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers α β II, a β III, and 2a β IV. J. Biol. Chem. 269, 10324-10329 (1994).
46. Hastie SB, Puett D, Mcdonald TL, Williams RC Jr. The binding of isocolchicine to tubulin. Mechanisms of ligand association with tubulin J. Biol. Chem. 264, 6682-6688 (1989).
47. Sengupta S, Banerjee S, Chakrabarti G, Mahapatra PK, Roy S, Bhattacharya B. NBD-isocolcemid-tubulin interaction: a novel one-step reaction involving no conformational adjustment of reactants. Biochemistry 39, 2227-2234 (2000)
48. Gordaliza M, Castro MA, Miguel del Corral JM, Feliciano AS. Antitumor properties of podophyllotoxin and related compounds. Curr. Pharm. Des. 6, 1811-1839 (2000).
49. Chattopadhyay S, Bisaria VS, Panda AK, Srivastava AK. Cytotoxicity of in vitro produced podophyllotoxin from Podophyllum bexandrum on human cancer cell line. Nat. Prod. Res. 18, 51-57 (2004).
50. Cortese F, Bhattacharyya B, Wolff J. Poclophyllotoxin as a probe for the colchicine binding site of tubulin. J. BioI. Chem. 252, 1134-1140 (1977).
51. Gupta S, Das L, Datta AB, Poddar A, Janik ME, Bhattacharyya B. Oxalone and lactone moieties of poclophyllotoxin exhibit properties of both the B and C rings of colchicine in its binding with tubulin. Biochemistry 45, 6467-6475 (2006).
52. Ohnuma T, Obata R, Nishiyama Y et al. Preparation and antitumor activity of 2″-O-, 3″ O- and 2″,3″ -di-O- substituted derivatives of etoposide. Chem. Pharm. Bull. 40, 1783-1788 (1992).
53. Palombo H, Estape J, Vinolas N et al. Chronic oral etoposide in advanced breast cancer. Cancer Chemother. Pharmacol. 33, 527-529 (1994).
54. Ziegler DS, Cohn RJ, McCowage G et al. Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors. Neuro-oncology 8, 53-59 (2006).
55. Liu SY, Hwang BD, Haruna M, Imakura Y, Lee KH, Cheng YC. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants. Mol. Pbarmacol. 36, 78-82 (1989).
56. Ji Z, Wang HK, Bastow KF et al. Antitumor agents 177. Design, synthesis, and biological evaluation of novel etoposide analogs bearing pyrrolecarboxamidino group as DNA topoisomerase II inhibitors. Bioorg. Med. Chem. Lett. 7, 607-612 (1997).
57. DeBrabander M, Van de Veine R, Aerts F, Geuens G, Borgers M, Janssen PAJ. The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubutes, on mammalian cells cultured in vitro. Cancer Res. 36, 905-916 (1976).
58. Head J, Lee LL, Field DJ, Lee JC. Equilibrium and rapid kinetic studies on nocodazole-tubulin interaction. J. Biol. Chem. 260, 11060-11066 (1985).
59. Friedman PA, Platzer EG. Interaction of antihelminthic benzimidazole and benzimidazole derivatives with bovine brain tubulin. Biochim. Biophys. Acta 554, 605-614 (1978).
60. Xu K, Schwarz PM, Ludueña RF. Interaction of nocodazole with tubulin isotypes. Drug Dev. Res. 55, 91-96 (2002).
61. Lin CM, Hamel E. Effects of inhibitors of tubulin polymerization on GTP hydrolysis. J. Biol. Chem. 256, 9242-9246 (1981).
62. Lee JC, Field DJ, Lee LLY. Effects of nocodazole on structures of calf brain tubulin. Biochemistry 19, 6209-6215 (1980).
63. Denyer CV, Reddy MT, Jenkins DC, Rapson E, Watts SDM. Synthesis of antitumour carbon-bridged imidazopyridazine carbamates. Arch. Pharm. 327, 95-98 (1994).
64. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 57, 3208-3213 (1997).
65. Shan B, Medina JC, Santha E et al. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Natl Acad. Sei. USA 92, 5686-5691 (1999).
66. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chem. Pharmacol. 42, 127-134 (1998).
67. Kirby S, Gertler SZ, Mason W et al. Phase 2 study of T138067-sodium in patients with malignant glioma: trial of the National Cancer Institute of the Canada clinical trials group. Neuro-oncology 7, 183-188 (2005).
68. Banerjee M, Poddar A, Mitra G, Surolia A, Owa T, Bhattacharyya B. Sulfonamide drugs binding to the colchicine site of tubulin: thermodynamic analysis of the drug-tubutin interactions by isothermal titration calorimetry. J. Med. Chem. 48, 547-555 (2005).
69. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28, 6984-6991 (1989).
70. Cirla A, Mann J. Combrelastatins: from natural products to drug discovery Nat. Prod. Rep. 20, 558-564 (2003).
71. Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. 13, 183-191 (1998).
72. Zhao S, Moore JV, Waller ML et al. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur. J. Nuclear Med. 26, 231-238 (1999).
73. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. 2, 82-87 (2001).
74. Leoni LM, Hamel E, Genini D et al. Indanocine, a microtubule-binding Indanone and a selective inducer Of apoptosis in multidrug-resistant cancer cells. J. Natl Cancer Inst. 92, 217-220 (2000).
75. Beckers T, Reissmann T, Schmidt M et al. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res. 62, 3113-3119 (2002).
76. Li L, Wang HK, Kuo SC et al. Antitumour agents 150. 2′3′4′5′5 6 7-substituted 2-phenyl-4quinolones and related compounds: their synthesis, cytotoxicity and inhibition of tubulin polymerisation. J. Med. Cbem. 37, 1126-1135 (1994).
77. Ni L, Meng CQ, Sikorski JA. Receni advances in therapeutic chalcones. Exp. Opin. Ther. Pat. 14, 1669-1691 (2004).
78. Sengupta S, Smitha SL, Nisha ET et al. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DATl): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system. Br. J. Pharmacol. 145, 1076-1083 (2005).
79. Jassem J, Kosmidis P, Ramlau R et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann. Oncol. 14, 1634-1639 (2003).
80. Rossi A, Gridelli C, Gebbia V et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res. 23, 1657-1664 (2003).
81. Duflos A, Druczynski A, Barret JM. Novel aspects of natural and modified Vinca alkaloids. Curr. Med. Chem. Anticancer Agents. 2, 55-70 (2002).
82. Gebbia V, Galletta D, Riccardi F et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study. Lung Cancer 37, 179-187 (2002).
83. Gigant B, Wang C, Ravelli RBG et al. Structural basis for the regulation of tubulin by vinblastine. Nature 435, 519-522 (2005).
84. Rai SS, Wolff J. Localization of the vinblastine-binding site on β-tubulin. J. Biol. Chem. 271, 14707-14711 (1996).
85. Bhattacharyya B, Wolff J. Tubulin aggregation and disaggregation: mediation by two distinct vinblastine-binding sites. Proc. Natl Acad. Sci. USA 73, 2375-2378 (1976)
86. H-labeled vinblastine binding to vinblastine-tubulin crystals. J. Mol. Biol. 121, 255-264 (1978).
87. Wilson L. Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. Biochemistry 9, 4999-5007 (1970).
88. Na GC, Timasheff SN. In vitro vinblastine-induced tubulin paracrystals. J. Biol. Chem. 257, 10387-10391 (1982).
89. Lobert S, Fahy J, Hill BT Duflos S, Etievant C, Correia JJ. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry 39, 12053-12062 (2000).
90. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35, 6806-6814 (1996).
91. Lobert S, Frankfurter A, Correia JJ. Binding of vinblastine to phosphocellulose-purified and α β-class III tubulin: the role of nucleotides and β-tubulin isotypes. Biochemistry 34, 8050-8060 (1995).
92. Singer WD, Jordan MA, Wilson L, Himes RH. Binding of vinblastine to stabilized microtubules. Mol. Pharmacol. 36, 366-370 (1989).
93. Jordan MA, Margoli RL, Himes RH, Wilson L. Identification of a distinct class of vinblastine binding sites on microtubules. J. Mol. Biol. 187, 61-73 (1986).
94. Bai RL, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 39, 1941-1949 (1990).
95. Tahir SK, Nukkala MA, Mozny NAZ et al. Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol. Cancer Therapeutics 2, 227-233 (2003).
96. Panda D, DeLuca K, Williams D, Jordan MA, Wilson L. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc. Natl Acad. Sci. USA 95, 9313-9318 (1998).
97. Mellado B, Font A, Aparicio LA et al. Phase II trial of weekly docetaxel (D) and complete androgen blockade (CAB) prior to radical prostatectomy (RP) in high-risk localized prostate cancer (PC) patients (pts). J. Clin. Oncol. 24, 14515 (2006).
98. D'Agostino G, del Campo J, Mellado B et al. A multicenter Phase II study of the cryptophycin analog LY355703 in patients with platinum- resistant ovarian cancer. Int. J. Gynecol. Cancer. 16, 71-76 (2006).
99. Wagner HP. Cell cycle control and cancer. Indian J. Pediatr. 65, 805-814 (1998).
100. Smith CD, Zhang X, Mooberry SL, Patterson GM, Moore RE. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res. 54, 3779-3784 (1994).
101. Smith CD, Zhang X. Mechanism of action cryptophycin. Interaction with the vinca alkaloid domain of tubulin. J. Biol. Chem. 271, 6192-6198 (1996).
102. Trimurtulu G, Ogino J, Heltzel CE et al. Structure determination, conformational-analysis, chemical-stability studies, and antitumor evaluation of the cryptophycins - isolation of 18 new analogs from nostoc sp strain gsv-224. J. Am. Chem. Soc. 117, 12030-12049 (1995).
103. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH. Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett. 377, 59-61 (1995).
104. Panda D, Anathnarayan V, Larson G, Shih C, Jordan MA, Wilson L. Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochemistry 39, 14121-14127 (2000).
105. Erikson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 66, 4426-4433 (2006)
106. Jordan A, Hadfield JA, Lawrence NJ, McGown Al Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 18, 259-296 (1998).
107. Takahashi M, Iwasaki S, Kobayashi H et al. Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues J. Antibiot. (Tokyo) 40, 66-72 (1987).
108. Li Y, Kobayashi H, Tokiwa Y, Hashimoto Y, Iwasaki S. Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site. Biochem. Pharmacol. 43, 219-224 (1992).
109. Chaudhuri AR, Luduena RF. Interaction of phomopsin A with normal and subtilisin-treated bovine brain tubulin. J. Protein Chem. 16, 99-105 (1997).
110. Bai R, Durso NA, Sackett DL, Hamel E Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38, 14302-14310 (1999).
111. Rawat DS, Joshi MC, Joshi P, Atheava II. Marine peptides and related compounds in clinical trial. Anticancer Agents Med Chem. 6, 33-40 (2006).
112. Anderson HJ, Coleman JE, Andersen RJ, Roberge M. Cytotoxic peptides hemiasterlin, hermasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother. Pharmacol. 39, 223-226 (1997).
113. Nunes M, Kaplan J, Wooters J et al. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label α-tubulin. Biochemistry 44, 6844-6857 (2005).
114. Cruz-Monserrate Z, Vervoort HC, Bai R et al. Diazonamide A and a synthetic structural analogue. Disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol. Pharmacol. 63, 1273-1280 (2003).
115. Pitor HC, McElroy EA Jr, Reid JM et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res. 5, 525-531 (1999).
116. Vaishampayan U, Glode M, Du W et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin. Cancer Res. 6, 4205-4208 (2000).
117. Bai R, Taylor GF, Schmidt JM et al. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Mol. Pharmacol. 47, 965-976 (1995).
118. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882-15889 (1991).
119. Fodstad O, Breistol K, Pettit GR, Shoemaker RH, Boyd MR. Comparative antiturnour activities of halichondrins and vinblastine against human tumour xenografts. J. Exp. Ther. Oncol. 1, 119-125 (1996).
120. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086-1095 (2005).
121. Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E, Spongistatin I. a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol. Pharm, 44, 757-766 (1993).
122. Bai R, Taylor GF, Cichacz ZA et al. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vincadomain. Biochemistry 34, 9714-9721 (1995).
123. Pettit GR, Cichacz ZA, Gao F et al. Isolation and structure of spongistatin 1. J. Org. Chem. 58, 1302-1304 (1993).
124. Kobayashi M, Aoki S, Sakai H et al. A potent anti-tumor macrolide from the Okinawan marine sponge Hyrtios altum. Tetrahedron Lett. 34, 2795-2798 (1993).